RxDoctor Payments Data

Cathy Hostettler

Nurse Practitioner · Iowa City, IANPI 1174504310

Payments from drug & device makers

$855in general payments, 2019–2025

Across 17 payments — averaging $50.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$159
  • AbbVie$154
  • Sanofi-aventis U.S. LLC$140
  • Boehringer Ingelheim$118
  • E.r. Squibb & Sons, L.L.C.$73
  • Insulet Corporation$45
  • plus $167 from 5 others

What the payments were for

  • Food & beverage$855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$855 in reported general payments places this provider in the 80th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$44,709
Medicare patients
160
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$54,867
EliquisApixaban48$37,408
TrulicityDulaglutide20$23,271
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,989
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$10,997
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,566
Gabapentin94$2,879
Levothyroxine Sodium209$1,692
Rosuvastatin Calcium125$1,603
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,276
Fluticasone Propionate42$975
Atorvastatin Calcium186$910
Metformin Hcl ErMetformin Hcl93$853
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$833
Lisinopril149$739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$54,86737 claims
GSKTrelegy Ellipta, Anoro Ellipta$21$25,98640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →